[{"id":"2698d9cc-7b84-4f76-aa1a-1e9120402516","acronym":"MAVRiC","url":"https://clinicaltrials.gov/study/NCT07024706","created_at":"2025-06-21T13:19:49.221Z","updated_at":"2025-06-21T13:19:49.221Z","phase":"Phase 2","brief_title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","source_id_and_acronym":"NCT07024706 - MAVRiC","lead_sponsor":"AstraZeneca","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 11/30/2032","primary_completion_date":" 11/30/2032","study_txt":" Completion: 11/30/2032","study_completion_date":" 11/30/2032","last_update_posted":"2025-06-17"},{"id":"7d526185-7f46-4c4c-8f3a-7efa8cb4410a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03516617","created_at":"2021-01-18T17:18:31.951Z","updated_at":"2025-02-25T12:26:55.184Z","phase":"Phase 2","brief_title":"Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03516617","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 03/15/2030","primary_completion_date":" 03/15/2030","study_txt":" Completion: 03/15/2031","study_completion_date":" 03/15/2031","last_update_posted":"2025-02-24"},{"id":"7d8868d0-7506-42fd-b3db-474559dd352d","acronym":"19-C-0116","url":"https://clinicaltrials.gov/study/NCT04002947","created_at":"2021-01-18T19:40:23.873Z","updated_at":"2025-02-25T13:39:52.977Z","phase":"Phase 2","brief_title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04002947 - 19-C-0116","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-02-21"},{"id":"c70f6861-a666-4861-ad3d-2301e394ab62","acronym":"ASCEND","url":"https://clinicaltrials.gov/study/NCT02970318","created_at":"2021-01-17T17:36:01.594Z","updated_at":"2025-02-25T14:01:11.516Z","phase":"Phase 3","brief_title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","source_id_and_acronym":"NCT02970318 - ASCEND","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • Zydelig (idelalisib) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-19"},{"id":"be1f4791-7f5f-42b3-86ee-a6bfee99acee","acronym":"ASSURE","url":"https://clinicaltrials.gov/study/NCT04008706","created_at":"2021-01-18T19:41:49.844Z","updated_at":"2025-02-25T14:07:28.508Z","phase":"Phase 3","brief_title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04008706 - ASSURE","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • CD20 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • IGH mutation","tags":["TP53 • CD20 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-17"},{"id":"82e136f4-d38a-459f-8a3f-411cfccafc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495464","created_at":"2022-08-10T12:55:30.197Z","updated_at":"2025-02-25T15:00:33.482Z","phase":"Phase 1","brief_title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05495464","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-12"},{"id":"cf9e772d-2d61-448f-ba42-778f71f83dc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169737","created_at":"2021-01-18T20:20:34.948Z","updated_at":"2025-02-25T15:26:14.343Z","phase":"Phase 2","brief_title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT04169737","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 07/09/2026","primary_completion_date":" 07/09/2026","study_txt":" Completion: 07/09/2026","study_completion_date":" 07/09/2026","last_update_posted":"2025-02-10"},{"id":"b4bf5e45-657b-45ed-b417-1f3548a2653e","acronym":"15-H-0016","url":"https://clinicaltrials.gov/study/NCT02337829","created_at":"2021-01-18T11:06:16.803Z","updated_at":"2025-02-25T17:29:13.836Z","phase":"Phase 2","brief_title":"Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL","source_id_and_acronym":"NCT02337829 - 15-H-0016","lead_sponsor":"Acerta Pharma BV","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/12/2015","start_date":" 01/12/2015","primary_txt":" Primary completion: 06/26/2020","primary_completion_date":" 06/26/2020","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-30"},{"id":"6fb8e6bc-6843-426e-b257-f87a181c8030","acronym":"","url":"https://clinicaltrials.gov/study/NCT04855695","created_at":"2021-04-22T20:53:44.057Z","updated_at":"2025-02-25T14:59:49.341Z","phase":"Phase 1/2","brief_title":"Avo In R/R And Previously Untreated MCL","source_id_and_acronym":"NCT04855695","lead_sponsor":"Austin I Kim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-29"},{"id":"41b81518-c725-4e13-b21e-3394ebef8619","acronym":"ACALLO","url":"https://clinicaltrials.gov/study/NCT04716075","created_at":"2021-03-14T06:44:32.030Z","updated_at":"2025-02-25T14:59:39.243Z","phase":"Phase 2","brief_title":"Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)","source_id_and_acronym":"NCT04716075 - ACALLO","lead_sponsor":"Polish Lymphoma Research Group","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 08/19/2019","start_date":" 08/19/2019","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2025-01-16"},{"id":"5a41cbea-814a-4e56-8dc2-a95f9d9a92ca","acronym":"CLL16","url":"https://clinicaltrials.gov/study/NCT05197192","created_at":"2022-01-19T16:53:41.712Z","updated_at":"2025-02-25T15:00:12.164Z","phase":"Phase 3","brief_title":"A Phase-3-trial of Acalabrutinib, Obinutuzumab \u0026 Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients with High Risk CLL","source_id_and_acronym":"NCT05197192 - CLL16","lead_sponsor":"German CLL Study Group","biomarkers":" TP53 • BCL2","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 650","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-12-30"},{"id":"5b915040-bf92-4ebb-9c29-3f40b90c8527","acronym":"","url":"https://clinicaltrials.gov/study/NCT05256641","created_at":"2022-02-25T16:52:35.078Z","updated_at":"2025-02-25T15:00:18.292Z","phase":"Phase 1/2","brief_title":"Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma","source_id_and_acronym":"NCT05256641","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/23/2023","start_date":" 01/23/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-11-05"},{"id":"f5de46f2-d18a-4c9b-9824-b8d60d25c24c","acronym":"RG1006269","url":"https://clinicaltrials.gov/study/NCT04257578","created_at":"2021-01-18T20:41:36.655Z","updated_at":"2025-02-25T14:58:51.439Z","phase":"Phase 1/2","brief_title":"Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma","source_id_and_acronym":"NCT04257578 - RG1006269","lead_sponsor":"University of Washington","biomarkers":" CD4","pipe":" | ","alterations":" CD19 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Yescarta (axicabtagene ciloleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2024-10-29"},{"id":"0e0b656b-b9de-434a-af64-37d19fbdf918","acronym":"","url":"https://clinicaltrials.gov/study/NCT03580928","created_at":"2021-01-17T17:37:10.768Z","updated_at":"2025-02-25T15:07:44.351Z","phase":"Phase 2","brief_title":"Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL","source_id_and_acronym":"NCT03580928","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • BCL2","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 08/07/2018","start_date":" 08/07/2018","primary_txt":" Primary completion: 04/10/2024","primary_completion_date":" 04/10/2024","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-07-30"},{"id":"1a4083a5-4479-438a-a119-f10ee1b03fe4","acronym":"PICAROS","url":"https://clinicaltrials.gov/study/NCT05999877","created_at":"2023-08-21T15:08:51.118Z","updated_at":"2024-07-02T16:34:26.928Z","phase":"","brief_title":"PICAROS - Acalabrutinib RWE on 1L CLL in Spain","source_id_and_acronym":"NCT05999877 - PICAROS","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation + Chr del(17p)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-12"},{"id":"aa10c497-874a-4e78-b3a1-858e57d57b8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198650","created_at":"2021-01-18T15:46:19.909Z","updated_at":"2024-07-02T16:34:27.508Z","phase":"Phase 1","brief_title":"A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies","source_id_and_acronym":"NCT03198650","lead_sponsor":"AstraZeneca","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 06/27/2017","start_date":" 06/27/2017","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-06-11"},{"id":"6dc76f3c-ed63-4771-a0a4-3ac73d6fddbc","acronym":"ELEVATE-TN","url":"https://clinicaltrials.gov/study/NCT02475681","created_at":"2021-01-17T17:35:21.456Z","updated_at":"2024-07-02T16:35:00.298Z","phase":"Phase 3","brief_title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","source_id_and_acronym":"NCT02475681 - ELEVATE-TN","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Leukeran (chlorambucil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 535","initiation":"Initiation: 06/26/2015","start_date":" 06/26/2015","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-29"},{"id":"73ba5444-927b-43fc-9089-82ed49c07d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT04765111","created_at":"2021-02-21T12:52:24.461Z","updated_at":"2024-07-02T16:35:03.612Z","phase":"Phase 2","brief_title":"Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT04765111","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2024-05-15"},{"id":"cc8eda31-2895-4431-a069-45bcfb4cb916","acronym":"","url":"https://clinicaltrials.gov/study/NCT05950997","created_at":"2023-07-20T14:08:33.285Z","updated_at":"2025-02-25T15:00:59.912Z","phase":"","brief_title":"A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL","source_id_and_acronym":"NCT05950997","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-05-09"},{"id":"25e24245-9e4c-4767-b5e7-b2e9ba8446f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983965","created_at":"2023-08-09T14:09:35.762Z","updated_at":"2024-07-02T16:35:05.238Z","phase":"Phase 1","brief_title":"Study of Tazemetostat in Lymphoid Malignancies","source_id_and_acronym":"NCT05983965","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CD4","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-08"},{"id":"efd59895-a4a3-45ee-9e4d-3b6abf4629a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04560322","created_at":"2021-01-18T21:47:42.558Z","updated_at":"2024-07-02T16:35:05.221Z","phase":"Phase 2","brief_title":"Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL","source_id_and_acronym":"NCT04560322","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/19/2020","start_date":" 10/19/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-08"},{"id":"fa4c40ce-a874-4bf2-93ea-d0fcb6f11e59","acronym":"","url":"https://clinicaltrials.gov/study/NCT04189757","created_at":"2021-01-18T20:25:19.472Z","updated_at":"2024-07-02T16:35:05.208Z","phase":"Phase 2","brief_title":"Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma","source_id_and_acronym":"NCT04189757","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/07/2020","start_date":" 08/07/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-08"},{"id":"27c7ff68-088f-4144-bc55-5bc4b6d717fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06054776","created_at":"2023-09-26T16:12:21.695Z","updated_at":"2024-07-02T16:35:08.820Z","phase":"Phase 2","brief_title":"Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT06054776","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/10/2024","start_date":" 06/10/2024","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-04-18"},{"id":"6d4d812a-6716-4ffb-85fc-6bad93889975","acronym":"","url":"https://clinicaltrials.gov/study/NCT03946878","created_at":"2021-01-18T19:25:54.987Z","updated_at":"2024-07-02T16:35:08.979Z","phase":"Phase 2","brief_title":"Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT03946878","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 02/08/2026","primary_completion_date":" 02/08/2026","study_txt":" Completion: 02/08/2026","study_completion_date":" 02/08/2026","last_update_posted":"2024-04-18"}]